Mehrian Jafarizade to Humans
This is a "connection" page, showing publications Mehrian Jafarizade has written about Humans.
Connection Strength
0.064
-
Jafarizade M, Kahe F, Sharfaei S, Momenzadeh K, Pitliya A, Zahedi Tajrishi F, Singh P, Chi G. The Role of Interleukin-27 in Atherosclerosis: A Contemporary Review. Cardiology. 2021; 146(4):517-530.
Score: 0.026
-
Kahe F, Sharfaei S, Pitliya A, Jafarizade M, Seifirad S, Habibi S, Chi G. Coronary artery tortuosity: a narrative review. Coron Artery Dis. 2020 03; 31(2):187-192.
Score: 0.006
-
Kerneis M, Nafee T, Yee MK, Kazmi HA, Datta S, Zeitouni M, Afzal MK, Jafarizade M, Walia SS, Qamar I, Pitliya A, Kalayci A, Al Khalfan F, Gibson CM. Most Promising Therapies in Interventional Cardiology. Curr Cardiol Rep. 2019 03 13; 21(4):26.
Score: 0.006
-
Chi G, Gibson CM, Kalayci A, Cohen AT, Hernandez AF, Hull RD, Kahe F, Jafarizade M, Sharfaei S, Liu Y, Harrington RA, Goldhaber SZ. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.
Score: 0.006
-
Chi G, Sharfaei S, Jafarizade M, Kahe F, Liu Y. Extended or shorter prophylaxis for venous thromboembolism in acutely ill hospitalized patients: Updated meta-analysis of randomized trials. Vasc Med. 2019 Apr; 24(2):156-158.
Score: 0.005
-
Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism. Expert Rev Cardiovasc Ther. 2018 Nov; 16(11):845-855.
Score: 0.005
-
Pitliya A, Datta S, Kalayci A, Kahe F, Sharfaei S, Jafarizade M, Goudarzi S, Chi G. Eosinophilic inflammation in spontaneous coronary artery dissection: A potential therapeutic target? Med Hypotheses. 2018 Dec; 121:91-94.
Score: 0.005
-
Chi G, Jamil A, Radulovic M, Jamil U, Balouch MA, Marszalek J, Karimi Z, Pahlavani S, Jafarizade M, Shaukat H, Kumar S, Kalayci A. Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy. Med Hypotheses. 2018 May; 114:40-44.
Score: 0.005